HomeComparePSBP vs ABBV

PSBP vs ABBV: Dividend Comparison 2026

PSBP yields 0.78% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.6K in total portfolio value
10 years
PSBP
PSBP
● Live price
0.78%
Share price
$25.50
Annual div
$0.20
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$82.53
Full PSBP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PSBP vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSBPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSBP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSBP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSBP
Annual income on $10K today (after 15% tax)
$66.67/yr
After 10yr DRIP, annual income (after tax)
$70.15/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,985.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSBP + ABBV for your $10,000?

PSBP: 50%ABBV: 50%
100% ABBV50/50100% PSBP
Portfolio after 10yr
$61.6K
Annual income
$12,427.15/yr
Blended yield
20.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PSBP
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSBP buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSBPABBV
Forward yield0.78%3.06%
Annual dividend / share$0.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$20.8K$102.3K
Annual income after 10y$82.53$24,771.77
Total dividends collected$806.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSBP vs ABBV ($10,000, DRIP)

YearPSBP PortfolioPSBP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,778$78.43$11,550$430.00$772.00ABBV
2$11,612$79.01$13,472$627.96$1.9KABBV
3$12,504$79.55$15,906$926.08$3.4KABBV
4$13,460$80.06$19,071$1,382.55$5.6KABBV
5$14,482$80.54$23,302$2,095.81$8.8KABBV
6$15,577$80.99$29,150$3,237.93$13.6KABBV
7$16,749$81.41$37,536$5,121.41$20.8KABBV
8$18,003$81.81$50,079$8,338.38$32.1KABBV
9$19,346$82.18$69,753$14,065.80$50.4KABBV
10$20,782$82.53$102,337$24,771.77$81.6KABBV

PSBP vs ABBV: Complete Analysis 2026

PSBPStock

PSB Holding Corp. operates as the holding company for Provident State Bank, Inc. that provides various banking products and services to individuals, small businesses, associations, and government entities. The company offers checking and savings accounts; and overdraft lines of credit, construction loans, home equity lines of credit, installment loans, residential mortgages, manufactured home loans, unimproved land loans, vehicle and boat loans, residential fixed-rate mortgages, business lines of credit, commercial loans and mortgages, commercial letters of credit, equipment and vehicle loans, and agricultural loans. It also provides cash management services; and personal and business check cards, credit and debit cards, wire transfers, night depository services, notary services, cash advances, e-statement services, safe deposit boxes, automated teller machine services, and bill payment services, as well as direct deposit of payroll and social security checks, and automatic drafts from accounts. In addition, the company offers online, mobile, and telephone banking services. It primarily operates in Caroline, Dorchester, Talbot, and Wicomico counties in Maryland; and Sussex County in Delaware. The company was founded in 1904 and is based in Preston, Maryland.

Full PSBP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PSBP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSBP vs SCHDPSBP vs JEPIPSBP vs OPSBP vs KOPSBP vs MAINPSBP vs JNJPSBP vs MRKPSBP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.